Akinyemi Oni-Orisan, PharmD, PhD

Assistant Professor
Department of Clinical Pharmacy
Oni-Orisan
Anna Wu
[email protected]
Phone: +1 415 502-7551
Fax: +1 415 476-1356
513 Parnassus Avenue, MSB, Rm 966B
UCSF Box 0794
San Francisco, CA 94143
United States

Links

UCSF Profiles

Affiliations

Education programs

PharmD Degree Program
Pharmaceutical Sciences and Pharmacogenomics (PSPG) PhD Program

School committees and service

Anti-Racist Curriculum Task Force, 2021, University of California San Francisco
DEI-AR Genetics Education Workgroup, 2020, University of California San Francisco

Department committees and service

Diversity Leader, 2021-present, Department of Clinical Pharmacy
DEI-AR Committee, 2022-present, Department of Clinical Pharmacy

What I do

My lab conducts computational research investigating therapies for cardiovascular disease using observational data from electronic health records. I also teach pharmacy students in the Discovery Projects research program including leading the Health Disparities Discovery Group and serving as a primary mentor for students in the Pharmacogenomics Discovery Group.

Departmental research area

clinical research

My research expertise

pharmacogenomics, pharmacoepidemiology, clinical research in historically minoritized groups, electronic health records

Clinical expertise

cardiovascular disease risk reduction, lipid management

Professional background

Degrees

PhD, Pharmacotherapy and Experimental Therapeutics, University of North Carolina
PharmD, University of Michigan
BS, Biology, University of Michigan

Training and professional development

Diversity, Equity, and Inclusion Champion Training, University of California San Francisco, 2022
Career Conversations, University of California San Francisco, 2022
Tea House Series Facilitator Training, University of California San Francisco, 2021

Biography

The long-term research goal of Dr. Oni-Orisan’s lab is to improve pharmacological regimens for the prevention and treatment of cardiovascular disease in diverse populations through precision medicine. To accomplish this objective, his group combines computational approaches in pharmacogenomics and pharmacoepidemiology using electronic health record-linked biobanks. His lab is currently funded to investigate genetic determinants of efficacy and safety for statin therapy in diverse populations.

Dr. Oni-Orisan teaches and mentors pharmacy students in the Discovery Projects research program including leading the inaugural Health Disparities Discovery Group.

Dr. Oni-Orisan serves as Diversity Leader for the Department of Clinical Pharmacy to champion diversity, equity and inclusion (DEI) efforts in the department.

Research keywords

  • pharmacogenomics
  • health disparities
  • Cardiovascular drugs
  • Amino Acid Substitution
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Eicosanoids
  • Epoxide Hydrolases
  • Arachidonic Acids
  • precision medicine
  • Cholesterol, LDL
  • Arachidonic Acid
  • Myocardial Infarction
  • pharmacogenetics
  • Patient Acuity
  • Cytochrome P-450 Enzyme System
  • Lovastatin
  • Acute Coronary Syndrome
  • Electronic Health Records

Publications

Oni-Orisan A, Lu M, Peng JA, Krauss RM, Iribarren C, Medina MW. Development and application of an algorithm for statin-induced myopathy based on electronic health record-derived structured elements. medRxiv. 2023 Apr 25.
Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A. Advancing CYP2D6 Pharmacogenetics Through a Pharmacoequity Lens. Clin Pharmacol Ther. 2023 Mar 16.
Brown K, Etrouth S, Jayachandran P, Moore J, Oni-Orisan A, Vasist L, Zheng S, Zhou Z, Dresser M. Diversity in Clinical Pharmacology: A Call to Action. Clin Pharmacol Ther. 2023 03; 113(3):483-485.
Hoffmann TJ, Lu M, Oni-Orisan A, Lee C, Risch N, Iribarren C. A large genome-wide association study of QT interval length utilizing electronic health records. Genetics. 2022 11 30; 222(4).
Oni-Orisan A, Haldar T, Cayabyab MAS, Ranatunga DK, Hoffmann TJ, Iribarren C, Krauss RM, Risch N. Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population. Clin Pharmacol Ther. 2022 11; 112(5):1070-1078.
Haldar T, Oni-Orisan A, Hoffmann TJ, Schaefer C, Iribarren C, Krauss RM, Medina MW, Risch N. Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort. Cardiovasc Diabetol. 2022 07 14; 21(1):132.
Wang EY, Breyer BN, Lee AW, Rios N, Oni-Orisan A, Steinman MA, Sim I, Kenfield SA, Bauer SR. Perceptions of Older Men Using a Mobile Health App to Monitor Lower Urinary Tract Symptoms and Tamsulosin Side Effects: Mixed Methods Study. JMIR Hum Factors. 2021 Dec 24; 8(4):e30767.
Lee AW, Kenfield SA, Wang EY, Enriquez A, Oni-Orisan A, Steinman MA, Sim I, Breyer BN, Bauer SR. Tracking Lower Urinary Tract Symptoms and Tamsulosin Side Effects Among Older Men Using a Mobile App (PERSONAL): Feasibility and Usability Study. JMIR Form Res. 2021 Dec 10; 5(12):e30762.
Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Jorgenson E, Iribarren C. QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System. J Am Heart Assoc. 2021 10 05; 10(19):e018513.
Mantri N, Lu M, Zaroff JG, Risch N, Hoffmann T, Oni-Orisan A, Lee C, Iribarren C. Torsade de pointes: A nested case-control study in an integrated healthcare delivery system. Ann Noninvasive Electrocardiol. 2022 01; 27(1):e12888.
Giacomini KM, Karnes JH, Crews KR, Monte AA, Murphy WA, Oni-Orisan A, Ramsey LB, Yang JJ, Whirl-Carrillo M. Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. Clin Pharmacol Ther. 2021 09; 110(3):559-562.
Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Risch N, Iribarren C, Krauss RM, Oni-Orisan A. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin. Clin Pharmacol Ther. 2021 09; 110(3):733-740.
Oni-Orisan A, Srinivas N, Mehta K, Das JL, Nguyen TT, Tison GH, Bauer SR, Burian M, Funk RS, Graham RA, Biomarkers and Translational Tools Community Working Group of the American Society for Clinical Phar. Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing. Clin Transl Sci. 2021 05; 14(3):784-790.
Oni-Orisan A, Mavura Y, Banda Y, Thornton TA, Sebro R. Embracing Genetic Diversity to Improve Black Health. N Engl J Med. 2021 Mar 25; 384(12):1163-1167.
Bauer SR, Breyer BN, Oni-Orisan A, Steinman MA, Sim I, McCulloch CE, Kenfield SA. PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms. Front Digit Health. 2020; 2:7.
Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ. The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom Med. 2020; 5:1.
Fohner AE, Ranatunga DK, Thai KK, Lawson BL, Risch N, Oni-Orisan A, Jelalian AT, Rettie AE, Liu VX, Schaefer CA. Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system. Pharmacogenet Genomics. 2019 10; 29(8):192-199.
Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circ Genom Precis Med. 2018 09; 11(9):e002043.
Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, Lee CR. Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. Prostaglandins Other Lipid Mediat. 2018 09; 138:15-22.
Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, Lee CR, Wiltshire T. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics. 2018 06 01; 19(9):771-782.
Akinyemi Oni-Orisan, Thomas Hoffmann, Marisa Medina, Eric Jorgenson, Catherine Schaefer, Ronald Krauss, Carlos Iribarren, Neil Risch. Validation of Electronic Health Records for the Assessment of Statin Dosing In Research. Journal of Clinical Lipidology. 2017 May 1; 11(3):836-837.
Bai X, Mangum KD, Dee RA, Stouffer GA, Lee CR, Oni-Orisan A, Patterson C, Schisler JC, Viera AJ, Taylor JM, Mack CP. Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. J Clin Invest. 2017 Feb 01; 127(2):670-680.
Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, Lee CR. Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study. J Lipid Res. 2016 Jan; 57(1):109-19.
Oni-Orisan A, Lanfear DE. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014 Sep-Oct; 22(5):193-8.
Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J Mol Cell Cardiol. 2014 Sep; 74:199-208.
Cicci JD, Reed BN, McNeely EB, Oni-Orisan A, Patterson JH, Rodgers JE. Acute decompensated heart failure: evolving literature and implications for future practice. Pharmacotherapy. 2014; 34(4):373-88.
Oni-Orisan A, Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, Lee CR. Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug; 104-105:67-73.
Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, Lee CR. Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Am J Physiol Endocrinol Metab. 2012 Mar 01; 302(5):E500-9.